Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Liabilities from Discontinued Operations (2021 - 2023)

Insight Molecular Diagnostics' Liabilities from Discontinued Operations history spans 3 years, with the latest figure at 45000.0 for Q4 2023.

  • For Q4 2023, Liabilities from Discontinued Operations fell 97.76% year-over-year to 45000.0; the TTM value through Dec 2023 reached 45000.0, down 97.76%, while the annual FY2023 figure was 45000.0, 97.76% down from the prior year.
  • Liabilities from Discontinued Operations for Q4 2023 was 45000.0 at Insight Molecular Diagnostics, down from 90000.0 in the prior quarter.
  • Across five years, Liabilities from Discontinued Operations topped out at 2005000.0 in Q4 2022 and bottomed at 45000.0 in Q4 2023.
  • The 3-year median for Liabilities from Discontinued Operations is 185500.0 (2023), against an average of 672833.33.
  • The largest annual shift saw Liabilities from Discontinued Operations skyrocketed 31.39% in 2022 before it plummeted 97.76% in 2023.
  • A 3-year view of Liabilities from Discontinued Operations shows it stood at 1526000.0 in 2021, then surged by 31.39% to 2005000.0 in 2022, then tumbled by 97.76% to 45000.0 in 2023.
  • Per Business Quant, the three most recent readings for IMDX's Liabilities from Discontinued Operations are 45000.0 (Q4 2023), 90000.0 (Q3 2023), and 135000.0 (Q2 2023).